Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Author
Abstract
Suggested Citation
DOI: 10.1007/s40273-019-00792-7
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
- Rumona Dickson & Angela Boland & Rui Duarte & Eleanor Kotas & Nerys Woolacott & Robert Hodgson & Rob Riemsma & Sabine Grimm & Bram Ramaekers & Manuela Joore & Nasuh Büyükkaramikli & Eva Kaltenthaler &, 2018. "EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties," Applied Health Economics and Health Policy, Springer, vol. 16(4), pages 429-432, August.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Paula K. Lorgelly & Amanda Adler, 2020. "Impact of a Global Pandemic on Health Technology Assessment," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 339-343, June.
- Kisser, Agnes & Tüchler, Heinz & Erdös, Judit & Wild, Claudia, 2016. "Factors influencing coverage decisions on medical devices: A retrospective analysis of 78 medical device appraisals for the Austrian hospital benefit catalogue 2008–2015," Health Policy, Elsevier, vol. 120(8), pages 903-912.
- Iyn-Hyang Lee & Karen Bloor & Eun-Young Bae, 2023. "A Comparative Analysis of Anticancer Drug Appraisals Including Managed Entry Agreements in South Korea and England," Applied Health Economics and Health Policy, Springer, vol. 21(2), pages 347-359, March.
- Sabine E. Grimm & Xavier Pouwels & Bram L. T. Ramaekers & Ben Wijnen & Thomas Otten & Janneke Grutters & Manuela A. Joore, 2021. "State of the ART? Two New Tools for Risk Communication in Health Technology Assessments," PharmacoEconomics, Springer, vol. 39(10), pages 1185-1196, October.
- Fernando Antonanzas & Carmelo Juárez-Castelló & Reyes Lorente & Roberto Rodríguez-Ibeas, 2019. "The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments," PharmacoEconomics, Springer, vol. 37(12), pages 1469-1483, December.
- Seung-Lai Yoo & Dae-Jung Kim & Seung-Mi Lee & Won-Gu Kang & Sang-Yoon Kim & Jong Hyuk Lee & Dong-Churl Suh, 2019. "Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System," IJERPH, MDPI, vol. 16(2), pages 1-15, January.
- Kasper M. Johannesen & Karl Claxton & Mark J. Sculpher & Allan J. Wailoo, 2018. "How to design the cost‐effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework," Health Economics, John Wiley & Sons, Ltd., vol. 27(2), pages 41-54, February.
- Matthew Franklin & James Lomas & Simon Walker & Tracey Young, 2019. "An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 37(5), pages 631-643, May.
- Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
- Reyes Lorente & Fernando Antonanzas & Roberto Rodriguez-Ibeas, 2019. "Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists," Health Economics Review, Springer, vol. 9(1), pages 1-8, December.
- A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
- Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
- Frederick W. Thielen & Nasuh C. Büyükkaramikli & Rob Riemsma & Debra Fayter & Nigel Armstrong & Ching-Yun Wei & Vanesa Huertas Carrera & Kate Misso & Gill Worthy & Jos Kleijnen & Isaac Corro Ramos, 2019. "Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma," PharmacoEconomics, Springer, vol. 37(8), pages 975-984, August.
- Christopher McCabe & Mike Paulden & Isaac Awotwe & Andrew Sutton & Peter Hall, 2020. "One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit," PharmacoEconomics, Springer, vol. 38(2), pages 135-141, February.
- Hester V Eeren & Saskia J Schawo & Ron H J Scholte & Jan J V Busschbach & Leona Hakkaart, 2015. "Value of Information Analysis Applied to the Economic Evaluation of Interventions Aimed at Reducing Juvenile Delinquency: An Illustration," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-15, July.
- Elsa Bouée-Benhamiche & Philippe Jean Bousquet & Salah Ghabri, 2020. "Economic Evaluations of Anticancer Drugs Based on Medico-Administrative Databases: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 18(4), pages 491-508, August.
- Haitham W. Tuffaha & Paul A. Scuffham, 2018. "The Australian Managed Entry Scheme: Are We Getting it Right?," PharmacoEconomics, Springer, vol. 36(5), pages 555-565, May.
- Christopher McCabe & Richard Edlin & Peter Hall, 2013. "Navigating Time and Uncertainty in Health Technology Appraisal: Would a Map Help?," PharmacoEconomics, Springer, vol. 31(9), pages 731-737, September.
- Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo, 2017. "The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment," PharmacoEconomics, Springer, vol. 35(12), pages 1287-1296, December.
- Sabine E. Grimm & Nigel Armstrong & Bram L. T. Ramaekers & Xavier Pouwels & Shona Lang & Svenja Petersohn & Rob Riemsma & Gillian Worthy & Lisa Stirk & Janine Ross & Jos Kleijnen & Manuela A. Joore, 2019. "Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 37(5), pages 655-667, May.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:10:d:10.1007_s40273-019-00792-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.